Compiles the most current information on the Zika virus and its associated diseases

This comprehensive book provides the most up-to-date information for students, medical students, and scientists on Zika virus and its associated diseases. It includes all the information related to the Zika virus since its discovery in 1947; its epidemic outbreak in 2007-2014; how the epidemiology changed in America in 2015-2016; its mode of transmission; how to prevent and treat it; and associated diseases.

Zika Virus and Diseases: From Molecular Biology to Epidemiology offers complete and up-to-date coverage in 10 chapters. It presents information from papers that attempted to associate the virus with diseases in Africa until the first animal experiment; discusses its association with Guillain-Barré syndrome and microcephaly; describes the basic mechanisms for Zika (ZIKV) replication, including important differences between Dengue (DENV), West-Nile virus (WNV), and ZIKV; explains the difference between the strains and discusses the pathogenesis of them; covers the papers that showed all the interferences that Zika can cause, and the pathways which can be modified; and more.

The first book since 1947 to put together all the scientific information
Compiles all the information received in the last year about Zika virus
Clearly demonstrates the origin and discovery of the virus
Zika Virus and Diseases: From Molecular Biology to Epidemiology will appeal to graduate students, medical students, basic researchers, clinicians in infectious disease, microbiology, and virology, as well as people in related disciplines interested in learning more about this topic.

About the Author
Suzane Ramos da Silva, Fan Cheng and Shou-Jiang Gao, Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.

Contents
Preface
List of Abbreviations

Chapter 1: The history of ZIKV discovery
1.1 ZIKV isolation from monkeys and mosquitos
1.2 ZIKV infection in humans
1.3 ZIKV infection spread to other hosts and regions
1.4 Cross-paths between ZIKV and other flaviviruses
References

Chapter 2: ZIKV: From silent to epidemic
2.1 Outbreak in Yap Island (2007)
2.2 Outbreak in French Polynesia (2013)
2.3 How did ZIKV reach Brazil?
2.4 Outbreak in Brazil (2015)
2.5 ZIKV spread through South, Central and North Americas
References

Chapter 3: ZIKV Transmission and Prevention
3.1 Modes of Transmission
3.2 Prevention
References

Chapter 4: Association with Guillain-Barré syndrome and microcephaly
4.1 Association with neurological disorders
References

Chapter 5: ZIKV animal models
5.1 Animal models: Embryonated hen eggs
5.2 Animal models: Landrace piglet
5.3 Animal models: Mice
5.4 Animal model non-human primate
References

Chapter 6: Biology of ZIKV
6.1 Structural and physical properties of ZIKV virion
6.2 Binding and entry
6.3 Genome structure
6.4 Translation and proteolytic processing
6.5 Features of the non-structural proteins
6.6 RNA replication
6.7 Features of the structural proteins
6.8 Virus assembly and release from virus-infected cells
References

Chapter 7: Zika virus (ZIKV) strains and lineages
7.1 East and West African lineage
7.2 Africa vs. Asian/American lineage
References

Chapter 8: ZIKV-host interactions
8.1 Systematic studies to identify ZIKV affected functions and pathways
8.2 Induction and dysregulation of innate immune responses during ZIKV infection
8.3 Induction of cell death and apoptosis by ZIKV
8.4 Induction of autophagy by ZIKV
8.5 Dysregulation of cell cycle and induction of abnormal mitosis by ZIKV
References

Chapter 9: Inhibitors of ZIKV replication and infection
9.1 Drugs that lead to the destruction of ZIKV virions
9.2 Drugs that inhibit ZIKV entry and endocytosis
9.3 Drugs that target ZIKV NS2B-NS3 protease activity
9.4 Drugs that target ZIKV NS5 RNA-dependent RNA polymerase activity
9.5 Neutralizing antibodies that target ZIKV structural protein
9.6 Drugs that inhibit ZIKV infection by targeting host machinery
9.7 Drugs that show neuroprotective activity but do not suppress ZIKV replication
9.8 Other drugs that inhibit ZIKV infection identified from a screening of FDA-approved drugs
References

Chapter 10: Long-term care and Perspectives
10.1 Prenatal care and diagnosis of abnormal fetus development
10.2 Long-term care for patients affected by ZIKV
10.3 Assistance to families with children affected by ZIKV
10.4 Perspectives
References

Index